公开(公告)号：AU2015333590A1

公开(公告)日：2017-04-20

申请号：AU2015333590

申请日：2015-10-14

Applicant: CELLMID LTD

Inventor： HALASZ MARIA ,  JONES DARREN ,  MERTENS NICO ,  CUNNAH PHILLIP

IPC: C07K16/22 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00

Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.

公开(公告)号：AU2015333590B2

公开(公告)日：2021-03-11

申请号：AU2015333590

申请日：2015-10-14

Applicant: CELLMID LTD

Inventor： HALASZ MARIA ,  JONES DARREN ,  MERTENS NICO ,  CUNNAH PHILLIP

IPC: C07K16/22 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00

Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.

公开(公告)号：EP3206712A4

公开(公告)日：2018-03-21

申请号：EP15849875

申请日：2015-10-14

Applicant: CELLMID LTD

Inventor： HALASZ MARIA ,  JONES DARREN ,  MERTENS NICO ,  CUNNAH PHILLIP

IPC: A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  C07K16/22

CPC classification number: C07K16/22 ,  A61K31/555 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/48546 ,  A61K47/48569 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57434 ,  G01N33/57488 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/475

Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.